rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BLTE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Belite Bio stock price target raised to $230 by Mizuho on FDA update
      Nov 16Investing.comBLTEMFG
      StoneX reiterates Buy rating on Belite Bio stock, $217 target
      Nov 13Investing.comBLTE
      What Belite Bio (BLTE) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceBLTE
      Earnings call transcript: Belite Bio tops Q3 2026 EPS view as FDA review advances
      Nov 12Investing.comBLTE
      Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
      Nov 12Yahoo FinanceBLTE
      Belite Bio (BLTE) Stock May Trade Above Fair Value On Book Value

      Belite Bio has delivered a very large 3 year share price gain, which puts fresh focus on whether the current US$157.69 quote can still be squared with what the balance sheet is worth. With that kind of move already on the table, the question now is how the book value stacks up against the market's expectations. The stock is up about 301% over the past 3 years, so a lot of future performance is already being debated through the lens of what investors are willing to pay over its accounting...

      Nov 10Yahoo FinanceBLTE
      Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceBLTE
      Belite Bio moves to Nasdaq Global Select Market
      Oct 19Investing.comBLTE
      Belite Bio Announces Uplisting to the Nasdaq Global Select Market
      Oct 19Yahoo FinanceBLTE
      Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
      Oct 17Yahoo FinanceBLTE
      Belite Bio stock price target maintained at $245 by H.C. Wainwright
      Oct 15Investing.comBLTE
      Belite Bio submits drug applications in Singapore, UK, Switzerland
      Oct 14Investing.comBLTE
      Belite Bio Submits Tinlarebant Applications in Three Markets for Rare Eye Disease
      Oct 14Yahoo FinanceBLTE
      Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
      Oct 14Yahoo FinanceBLTE
      Belite Bio CMO Scholl sells $82,658 in shares
      Oct 6Investing.comBLTE
      Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

      SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development ...

      Oct 1Business InsiderBLTE
      Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
      Sep 28Yahoo FinanceBLTE
      Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review
      Sep 15Investing.comBLTE
      Belite Bio at Morgan Stanley conference: tinlarebant nears key FDA test
      Sep 14Investing.comBLTEMS
      Belite Bio at Cantor healthcare conference: tinlarebant advances
      Sep 11Investing.comBLTE
      Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

      Tipranks Press Release.

      Sep 10The Globe and MailBLTEGPCR
      Belite Bio Insider Sold Shares Worth $12,803,528, According to a Recent SEC Filing
      Sep 10Yahoo FinanceBLTE
      Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs
      Sep 10Investing.comBLTE
      Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares
      Sep 10Investing.comBLTE
      Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

      When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

      Sep 9Yahoo FinanceBLTE
      Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing
      Sep 9Investing.comBLTE
      Mizuho raises Belite Bio stock price target on Japan drug filing
      Sep 9Investing.comBLTE
      Belite Bio On Track For A Potential Blockbuster Launch In 2027
      Sep 9Seeking AlphaBLTE
      Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating
      Sep 9Yahoo FinanceBLTE
      Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt...

      U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease ty...

      Sep 8Business InsiderBLTE
      Belite Bio submits drug application in Japan for Stargardt disease
      Sep 8Investing.comBLTE
      Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

      U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 and could become the first Sakigake pharmaceutical product for ophthalmology disease in Japan SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite

      Sep 8Yahoo FinanceBLTE
      Belite Bio at Wells Fargo conference: nda review lifts stakes
      Sep 8Investing.comBLTE
      Why Is Belite Bio Stock Soaring Friday?
      Sep 4BenzingaBLTE
      This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
      Sep 4BenzingaBLTELENPHM
      Canaccord initiates Belite Bio stock with buy on Stargardt therapy
      Sep 4Investing.comBLTE
      Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says

      Belite Bio's (BLTE) revenue estimates for tinlarebant to treat Stargardt disease type 1 have multipl

      Sep 4Yahoo FinanceBLTE
      Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target
      Sep 4Yahoo FinanceBLTE
      Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating
      Sep 4Yahoo FinanceBLTE
      H.C. Wainwright reiterates Belite Bio stock rating on commercial plans
      Sep 3Investing.comBLTE
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailBLTE
      Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

      Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date. At the company’s 2026 Commercial Day, Chairman and CEO

      Sep 3Yahoo FinanceBLTE
      Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 - Slideshow (NASDAQ:BLTE) 2026-09-02

      2026-09-02. The following slide deck was published by Belite Bio, Inc in conjunction with this event.

      Sep 3Seeking AlphaBLTE
      Belite Bio to Participate in Four Upcoming Investor Conferences

      SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) September 8, 2026, at 8:45 am E

      Sep 1Yahoo FinanceBLTE
      Belite Bio to Host Virtual Commercial Day on September 2, 2026

      SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development ...

      Aug 24Business InsiderBLTE
      Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

      SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Soc

      Aug 21Yahoo FinanceBLTE

      This is the newest page. Registered accounts read further back.